Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives

被引：31

作者：

Costa, R. ^{[1
,2
]}

Carneiro, B. A. ^{[1
,2
]}

Wainwright, D. A. ^{[3
,4
,5
]}

Santa-Maria, C. A. ^{[1
,2
]}

Kumthekar, P. ^{[4
]}

Chae, Y. K. ^{[1
,2
]}

Gradishar, W. J. ^{[1
,2
]}

Cristofanilli, M. ^{[1
,2
]}

Giles, F. J. ^{[1
,2
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Dev Therapeut Program, Chicago, IL 60611 USA

[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[3] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA

[4] Northwestern Univ, Dept Neurol, Feinberg Sch Med, Chicago, IL 60611 USA

[5] Northwestern Univ, Dept Microbiol Immunol, Feinberg Sch Med, Chicago, IL 60611 USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷 / 01期

关键词：

breast cancer; brain; targeted therapy; HER2; anti-angiogenesis; immunotherapy; BLOOD-BRAIN-BARRIER; ENHANCED CHEMOTHERAPY DELIVERY; ENDOTHELIAL GROWTH-FACTOR; CYCLIN-DEPENDENT KINASES; DINACICLIB SCH 727965; PHASE-II TRIAL; ANTITUMOR-ACTIVITY; SPORADIC BREAST; P-GLYCOPROTEIN; AURORA KINASE;

D O I：

10.1093/annonc/mdw532

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is the second-leading cause of metastatic disease in the central nervous system (CNS). Recent advances in the biological understanding of breast cancer have facilitated an unprecedented increase of survival in a subset of patients presenting with metastatic breast cancer. Patients with HER2 positive (HER2+) or triple negative breast cancer are at highest risk of developing CNS metastasis, and typically experience a poor prognosis despite treatment with local and systemic therapies. Among the obstacles ahead in the realm of developmental therapeutics for breast cancer CNS metastasis is the improvement of our knowledge on its biological nuances and on the interaction of the blood-brain barrier with new compounds. This article reviews recent discoveries related to the underlying biology of breast cancer brain metastases, clinical progress to date and suggests rational approaches for investigational therapies.

引用

页码：44 / 56

页数：13

共 165 条

[1] Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases [J].

Adamo, Barbara ;

Deal, Allison M. ;

Burrows, Emily ;

Geradts, Joseph ;

Hamilton, Erika ;

Blackwell, Kimberly L. ;

Livasy, Chad ;

Fritchie, Karen ;

Prat, Aleix ;

Harrell, J. Chuck ;

Ewend, Matthew G. ;

Carey, Lisa A. ;

Miller, C. Ryan ;

Anders, Carey K. .

BREAST CANCER RESEARCH, 2011, 13 (06)

[2] Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p2l, p27, and antiestrogens in breast cancer [J].

Akli, S ;

Zheng, PJ ;

Multani, AS ;

Wingate, HF ;

Pathak, S ;

Zhang, N ;

Tucker, SL ;

Chang, S ;

Keyomarsi, K .

CANCER RESEARCH, 2004, 64 (09) :3198-3208

[3] Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway [J].

Akli, Said ;

Van Pelt, Carolyn S. ;

Bui, Tuyen ;

Multani, Asha S. ;

Chang, Sandy ;

Johnson, David ;

Tucker, Susan ;

Keyomarsi, Khandan .

CANCER RESEARCH, 2007, 67 (15) :7212-7222

[4] Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation [J].

An, HX ;

Beckmann, MW ;

Reifenberger, G ;

Bender, HG ;

Niederacher, D .

AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (01) :113-118

[5]

[Anonymous], SAN ANT BREAST C 201

[6]

[Anonymous], SAN ANT BREAST C 201

[7]

[Anonymous], SAN ANT BREAST C 201

[8]

[Anonymous], PHAS I STUD MLN0128

[9]

[Anonymous], STUD AB LY2835219 WO

[10]

[Anonymous], AM ASS CANC RES ANN

← 1 2 3 4 5 6 7 8 9 10 →